- 21 September
-
On September 11–17, 2026, Ekaterinburg hosted the International Youth Festival, a large-scale event that brought together 10,000 young leaders from 191 countries. At the festival running under the motto «Follow Your Dream,» the Medsintez Plant presented its exhibition, showcasing the achievements of the Ural pharmaceutical industry in the field of import substitution.
- 18 September
-
The updated clinical guidelines for treatment of ARVI in children took effect on September 2, 2026. The document was developed by leading experts from the Union of Pediatricians of Russia, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), and the Russian Society of Emergency Medical Care and approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. It fundamentally shifts therapeutic approaches toward enhanced safety and minimal drug burden.
- 14 September
-
On September 3–4, 2026, Nizhny Novgorod hosted the 2nd Regional Endocrinological Congress: Challenges and Prospects of the Volga Region, with the active participation of the Medsintez Plant. As a strategic company, Medsintez Plant has been ensuring Russia's pharmaceutical security for 25 years. Company's exhibition booth showcased a range of hormonal medications for treatment of type 1 and type 2 diabetes, as well as drugs for infertility treatment through the IVF method.
- 04 September
-
More than twenty years ago, the Regiony Rossii (Regions of Russia, RR) magazine witnessed the birth of an innovative pharmaceutical production facility in Novouralsk, which had no analogues in the country. Today, the Medsintez Plant is a strategic asset in terms of national pharmaceutical security, a recognized industry leader, a National Champion, and a winner of prestigious awards. The secret behind the success of the Ural school of pharmaceuticals and biotechnology is explored in this article by RR.
- Home
- Cluster members
- Medsintez Plant LLC
Medsintez Plant LLC
.JPG)
Medsintez Plant LLC is a strategic company located in Novouralsk, which plays a key role in ensuring the safety of drug supply in the Russian Federation. Founded in 2003, the plant produces a wide range of import-substituting pharmaceutical products and in 2020, it was included in the list of systemic companies of the country. In 2025, the plant was awarded the status of National Champion, confirming its leadership in the industry.
In 2007, the Medsintez Plant became the first pharmaceutical company in Russia being awarded the Russian Government Prize for Quality. The key factors of success include an in-house research and development center, modern quality control laboratories, and a team having deep expertise in organizing manufacture in accordance with international GMP standards.
The company's strategy is focused on the development and production of active pharmaceutical ingredients and high-tech drugs based on modern technology platforms, including organic, biotechnological, solid-phase peptide, and combined synthesis.
Drugs for the treatment of diabetes. The enterprise implements fully integrated production of the whole product range of genetically engineered human insulin ROSINSULIN and analogue human insulins ROSINSULIN ASPART R and ROSINSULIN GLARGINE made of our own APIs. In collaboration with Promomed Group of Companies, a full-cycle production of hypoglycemic drugs for treatment of type 2 diabetes, Liraglutide and Semaglutide (GLP-1), has been established.
Drugs for the Treatment of Infertility. Primapur® is the first Russian drug of recombinant human follicle-stimulating hormone for human infertility treatment, used in the in vitro fertilization and included in the List of Vital and Essential Drugs. Primapur® is available in the form of an easy-to-use disposable injection pen. The company is developing a complete line of IVF medications to ensure drug safety in this area in Russia and allow independence from import supplies.
Antiviral drug TRIAZAVIRIN®. TRIAZAVIRIN® is a direct-acting antiviral drug developed by Russian scientists based on the original molecule. It is effective for the treatment and prevention of viral diseases, has a wide range of direct antiviral activity against RNA viral infections such as influenza, acute respiratory viral infection, COVID-19. TRIAZAVIRIN® is included in the clinical guidelines of the Russian Ministry of Health for the treatment of influenza and acute respiratory viral infections, and the prevention and treatment of COVID-19. A new dosage (100 mg) of TRIAZAVIRIN® for children aged 6-17 years was registered in 2025.
Veterinary Drugs. The plant also produces VINSUVET, the first Russian species-specific veterinary insulins for cats, dogs, and livestock.
Blood substitutes. The plant has established a full-cycle production of the world's first registered drug of recombinant human albumin for wide medical use.
Since 2024, Medsintez Plant has been implementing a major upgrade project aimed at expanding the production of drugs based on its own peptide and biotechnological substances (GLP-1 analogues, IVF medications). It will boost production volume and fully ensure independence for Russia in terms of essential groups of drugs.
One of the major directions for development of the Medsintez Plant is contract manufacturing. Among partners of the enterprise are the largest international pharmaceutical companies such as Bayer, STADA, iVFarma, Promomed, etc.
Today, the Medsintez Plant addresses systemic challenges, such as mastering innovative technologies in line with international standards, expanding into the global market, developing the R&D center, creating IT solutions for pharmaceuticals and medical technologies, as well as providing ongoing personnel training and social support.
15, Torgovaya St., Novouralsk, Sverdlovsk Region, Russia
Тel.: +7 (34370) 2-50-61
e-mail: medsintez@mail.ru
.png)
